Author: Rheumatology TT
-
Psoriatic Arthritis: What You Need To Know…
Psoriatic Arthritis (PsA) is a chronic inflammatory condition affecting 0.1% to 1% of the population, impacting over 20% of psoriasis patients. Symptoms include joint pain, swelling, and skin lesions, often occurring cyclically. It typically develops post-30 and requires a combination of physical evaluations and imaging for diagnosis and management.
-
National Osteoporosis Guidelines Group (NOGG) UK – Summary of Main Recommendations
Updated September 2024 This summary addresses the assessment, diagnosis and current treatments for osteoporosis, including recommendations to prevent fragility fractures. It applies to postmenopausal women, and to men age 50 years or older. Concerning assessment of fracture risk in postmenopausal women, and men age ≥50: Regarding drug treatment to prevent fractures in postmenopausal women, and…
-
World Health Organisation (WHO) Classification Criteria for Osteoporosis
Table adapted from Amarnath SS, et al. (2023) Classification of osteoporosis is based on BMD (Bone Mineral Density) testing with DEXA (Dual emission X-ray Absorptiometry). This classification devised by the WHO (World Health Organization) utilizes T-scores in BMD reporting of women in menopausal transition or postmenopause and men ≥ 50 years [2] References:
-
Vitamin D & Your Immune Health: What You Should Know
How Vitamin D Supports the Immune System Vitamin D works on many immune cells to reduce excessive inflammation while still fighting infections effectively [1],[6]. It helps boost natural defenses by supporting skin and gut barriers and increasing natural antimicrobial chemicals in the body. Vitamin D encourages the creation of important regulatory cells that help prevent the immune system…
-
2019 EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
Algorithm of glandular function assessment and therapeutic approach in patients with primary SjS presenting with oral dryness. SjS, Sjögren syndrome; SWSF, stimulated whole salivary flows; UWSF, unstimulated whole salivary flows. Algorithm of glandular function assessment and therapeutic approach in patients with primary SjS presenting with ocular dryness. *Consider neuropathic pain if OSS≤1. **Additional criteria for…
-
Overarching Principles and Recommendations in the Management of Gout
Overarching Principles A Every person with gout should be fully informed about the pathophysiology of the disease, the existence of effective treatments, associated comorbidities and the principles of managing acute attacks and eliminating urate crystals through lifelong lowering of SUA level below a target level. B Every person with gout should receive advice regarding lifestyle:…
-
2016 Updated EULAR Recommendations for Management of flares in patients with Gout
Management of acute flare according to the European League Against Rheumatism recommendations. Letters and numbers in parentheses indicate the items of the recommendations presented in the table. Strong P-glycoprotein or CYP3A4 inhibitors are cyclosporin, clarithromycin, ketoconazole and ritonavir. IL, interleukin; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; ULT, urate-lowering therapy.
-
The 2015 American College of Rheumatology/European Alliance of Associations for Rheumatology Gout Classification Criteria
Categories Score Step 1: Entry criterion (only apply criteria below to those meeting this entry criterion) At least 1 episode of swelling, pain, or tenderness in a peripheral joint or bursa Step 2: Sufficient criterion (if met, can classify as gout without applying criteria below) Presence of MSU crystals in a symptomatic joint or bursa (ie, in…
-
Overarching principles for treatment of Systemic Lupus Erythematosus
A. SLE requires multidisciplinary, individualised management with patient education and shared decision- making, taking into consideration the costs to patient and society B. SLE disease activity should be assessed at each clinic visit (the frequency depending on physician’s discretion), with evaluation of organ damage (at least annually), using validated instruments. C. Non- pharmacological interventions, including…
-
2023 EULAR recommendations for the management of systemic lupus erythematosus
Non-Renal Systemic Lupus Erythematosus Figure 1 Treatment of non- renal systemic lupus erythematosus. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis Epub doi:10.1136/ard-2023 224762 Top- to bottom sequence does not imply order of preference (eg, MTX, AZA and MMF are equal options for second- line therapy in mild…
Rheumatology TT 